Esophageal Cancer Clinical Trial

Lucid Registry Study

Summary

This is a multicenter, prospective, observational study designed to capture a limited set of data consisting of diagnostic test results and clinical management information on subjects who undergo EC/EG to assess for the presence of BE/EAC. Once sufficient time has elapsed for EsoGuard results to be available, as well as for any subsequent clinical evaluation to have been performed (e.g., upper endoscopy and any initial therapeutic management), study staff will obtain the desired information and record it in an electronic data collection (EDC) system, pertaining to subject demographics, pertinent medical history, and risk factors for BE or EAC as well as (1) information about the EsoCheck cell collection procedure and patient tolerance, (2) EsoGuard test result; (3) initial clinical management including upper endoscopy, if performed, and diagnosis (as determined by the endoscopist and the pathologist assessing any biopsies taken), as well as (4) additional clinical management and/or a therapeutic procedure(s) performed. The time point for collecting such information shall be fluid, depending on the time course of care provided subsequent to the EsoGuard result being available. It is expected typically to be approximately 4 months given the systemic delays in scheduling and performing upper endoscopies and obtaining biopsy results. There is no a priori limit on the timeline for obtaining these data, but it is . anticipated that all data collection will be completed within 8 months of the availability of EsoGuard results.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Males and Females who have provided informed consent for prospective registry participation
Subject in whom the clinical decision has been made to screen for BE/EAC using EsoGuard testing on samples collected with EsoCheck

Exclusion Criteria:

Inability to provide written informed consent
Subjects who fall outside the eligible population defined by the EsoCheck device Instructions For Use (IFU)

Study is for people with:

Esophageal Cancer

Estimated Enrollment:

500

Study ID:

NCT05965999

Recruitment Status:

Recruiting

Sponsor:

Lucid Diagnostics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

LUCID DX
Lake Forest California, 92630, United States More Info
Tiffany To
Contact

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Estimated Enrollment:

500

Study ID:

NCT05965999

Recruitment Status:

Recruiting

Sponsor:


Lucid Diagnostics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.